{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:55:16Z","timestamp":1740167716374,"version":"3.37.3"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Newcastle Annual Fund"},{"DOI":"10.13039\/501100007903","name":"Bloodwise","doi-asserted-by":"publisher","award":["15036","15036"],"award-info":[{"award-number":["15036","15036"]}],"id":[{"id":"10.13039\/501100007903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"The European Research Council","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A common problem in the study of human malignancy is the elucidation of cancer driver mechanisms associated with recurrent deletion of regions containing multiple genes. Taking B-cell acute lymphoblastic leukaemia (B-ALL) and large deletions of 6q [del(6q)] as a model, we integrated analysis of functional cDNA clone tracking assays with patient genomic and transcriptomic data, to identify the transcription factors FOXO3 and PRDM1 as candidate tumour suppressor genes (TSG). Analysis of cell cycle and transcriptomic changes following overexpression of <jats:italic>FOXO3<\/jats:italic> or <jats:italic>PRDM1<\/jats:italic> indicated that they co-operate to promote cell cycle exit at the pre-B cell stage. <jats:italic>FOXO1<\/jats:italic> abnormalities are absent in B-ALL, but like <jats:italic>FOXO3<\/jats:italic>, <jats:italic>FOXO1<\/jats:italic> expression suppressed growth of <jats:italic>TCF3::PBX1<\/jats:italic> and <jats:italic>ETV6::RUNX1<\/jats:italic> B-ALL in-vitro. While both FOXOs induced <jats:italic>PRDM1<\/jats:italic> and other genes contributing to late pre-B cell development, FOXO1 alone induced the key transcription factor, <jats:italic>IRF4<\/jats:italic>, and chemokine, <jats:italic>CXCR4<\/jats:italic>. CRISPR-Cas9 screening identified FOXO3 as a TSG, while FOXO1 emerged as essential for B-ALL growth. We relate this FOXO3-specific leukaemia-protective role to suppression of glycolysis based on integrated analysis of CRISPR-data and gene sets induced or suppressed by FOXO1 and FOXO3. Pan-FOXO agonist Selinexor induced the glycolysis inhibitor TXNIP and suppressed B-ALL growth at low dose (ID<jats:sub>50<\/jats:sub>\u2009&lt;\u200950\u2009nM).<\/jats:p>","DOI":"10.1038\/s41375-023-01816-0","type":"journal-article","created":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T04:06:46Z","timestamp":1674274006000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Disruption to the FOXO-PRDM1 axis resulting from deletions of chromosome 6 in acute lymphoblastic leukaemia"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7816-3895","authenticated-orcid":false,"given":"Paul B.","family":"Sinclair","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth E.","family":"Cranston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prahlad","family":"Raninga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoe","family":"Hawking","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0112-609X","authenticated-orcid":false,"given":"Steven","family":"Hair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarra L.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7464-0743","authenticated-orcid":false,"given":"Amir","family":"Enshaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sirintra","family":"Nakjang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2198-8949","authenticated-orcid":false,"given":"Vikki","family":"Rand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen J.","family":"Blair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9781-6107","authenticated-orcid":false,"given":"Anthony V.","family":"Moorman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5404-6483","authenticated-orcid":false,"given":"Olaf","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0526-6794","authenticated-orcid":false,"given":"Christine J.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,20]]},"reference":[{"key":"1816_CR1","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1182\/blood.V91.9.3397","volume":"91","author":"M Merup","year":"1998","unstructured":"Merup M, Moreno TC, Heyman M, Ronnberg K, Grander D, Detlofsson R, et al. 6q deletions in acute lymphoblastic leukemia and non-Hodgkin\u2019s lymphomas. Blood. 1998;91:3397\u2013400.","journal-title":"Blood."},{"key":"1816_CR2","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1182\/blood-2008-10-186536","volume":"114","author":"M Remke","year":"2009","unstructured":"Remke M, Pfister S, Kox C, Toedt G, Becker N, Benner A, et al. High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-beta and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response. Blood. 2009;114:1053\u201362.","journal-title":"Blood."},{"key":"1816_CR3","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1182\/blood-2012-12-474148","volume":"121","author":"BR Bonn","year":"2013","unstructured":"Bonn BR, Rohde M, Zimmermann M, Krieger D, Oschlies I, Niggli F, et al. Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence. Blood. 2013;121:3153\u201360.","journal-title":"Blood."},{"key":"1816_CR4","doi-asserted-by":"publisher","first-page":"E604","DOI":"10.1002\/ajh.24852","volume":"92","author":"M Jarosova","year":"2017","unstructured":"Jarosova M, Hruba M, Oltova A, Plevova K, Kruzova L, Kriegova E, et al. Chromosome 6q deletion correlates with poor prognosis and low relative expression of FOXO3 in chronic lymphocytic leukemia patients. Am J Hematol. 2017;92:E604\u2013E7.","journal-title":"Am J Hematol"},{"key":"1816_CR5","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/S0002-9440(10)64818-3","volume":"157","author":"LL Siu","year":"2000","unstructured":"Siu LL, Chan V, Chan JK, Wong KF, Liang R, Kwong YL. Consistent patterns of allelic loss in natural killer cell lymphoma. Am J Pathol. 2000;157:1803\u20139.","journal-title":"Am J Pathol"},{"key":"1816_CR6","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.ccr.2010.10.030","volume":"18","author":"J Mandelbaum","year":"2010","unstructured":"Mandelbaum J, Bhagat G, Tang H, Mo T, Brahmachary M, Shen Q, et al. BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell. 2010;18:568\u201379.","journal-title":"Cancer Cell"},{"key":"1816_CR7","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1182\/blood-2011-04-346890","volume":"118","author":"K Karube","year":"2011","unstructured":"Karube K, Nakagawa M, Tsuzuki S, Takeuchi I, Honma K, Nakashima Y, et al. Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses. Blood. 2011;118:3195\u2013204.","journal-title":"Blood."},{"key":"1816_CR8","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1182\/blood-2013-04-497933","volume":"122","author":"M Boi","year":"2013","unstructured":"Boi M, Rinaldi A, Kwee I, Bonetti P, Todaro M, Tabbo F, et al. PRDM1\/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. Blood. 2013;122:2683\u201393.","journal-title":"Blood."},{"key":"1816_CR9","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.cell.2011.09.035","volume":"147","author":"E Oricchio","year":"2011","unstructured":"Oricchio E, Nanjangud G, Wolfe AL, Schatz JH, Mavrakis KJ, Jiang M, et al. The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell. 2011;147:554\u201364.","journal-title":"Cell."},{"key":"1816_CR10","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.1158\/0008-5472.CAN-03-1871","volume":"64","author":"PB Sinclair","year":"2004","unstructured":"Sinclair PB, Sorour A, Martineau M, Harrison CJ, Mitchell WA, O\u2019Neill E, et al. A fluorescence in situ hybridization map of 6q deletions in acute lymphocytic leukemia: identification and analysis of a candidate tumor suppressor gene. Cancer Res. 2004;64:4089\u201398.","journal-title":"Cancer Res"},{"key":"1816_CR11","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/ncb3046","volume":"16","author":"N Li","year":"2014","unstructured":"Li N, Fassl A, Chick J, Inuzuka H, Li X, Mansour MR, et al. Cyclin C is a haploinsufficient tumour suppressor. Nat Cell Biol. 2014;16:1080\u201391.","journal-title":"Nat Cell Biol"},{"key":"1816_CR12","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/nm.3247","volume":"19","author":"S Swaminathan","year":"2013","unstructured":"Swaminathan S, Huang C, Geng H, Chen Z, Harvey R, Kang H, et al. BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. Nat Med. 2013;19:1014\u201322.","journal-title":"Nat Med"},{"key":"1816_CR13","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.it.2020.05.003","volume":"41","author":"KC McLean","year":"2020","unstructured":"McLean KC, Mandal M. It Takes Three Receptors to Raise a B Cell. Trends Immunol. 2020;41:629\u201342.","journal-title":"Trends Immunol"},{"key":"1816_CR14","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.celrep.2018.06.035","volume":"24","author":"CS Setz","year":"2018","unstructured":"Setz CS, Hug E, Khadour A, Abdelrasoul H, Bilal M, Hobeika E, et al. PI3K-Mediated Blimp-1 Activation Controls B Cell Selection and Homeostasis. Cell Rep. 2018;24:391\u2013405.","journal-title":"Cell Rep"},{"key":"1816_CR15","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/leu.2012.206","volume":"27","author":"S Bomken","year":"2013","unstructured":"Bomken S, Buechler L, Rehe K, Ponthan F, Elder A, Blair H, et al. Lentiviral marking of patient-derived acute lymphoblastic leukaemic cells allows in vivo tracking of disease progression. Leukemia. 2013;27:718\u201321.","journal-title":"Leukemia."},{"key":"1816_CR16","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1089\/10430340252898984","volume":"13","author":"C Demaison","year":"2002","unstructured":"Demaison C, Parsley K, Brouns G, Scherr M, Battmer K, Kinnon C, et al. High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther. 2002;13:803\u201313.","journal-title":"Hum Gene Ther"},{"key":"1816_CR17","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3324\/haematol.2017.172304","volume":"103","author":"PB Sinclair","year":"2018","unstructured":"Sinclair PB, Blair HH, Ryan SL, Buechler L, Cheng J, Clayton J, et al. Dynamic clonal progression in xenografts of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21. Haematologica. 2018;103:634\u201344.","journal-title":"Haematologica."},{"key":"1816_CR18","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1038\/leu.2016.80","volume":"30","author":"SL Ryan","year":"2016","unstructured":"Ryan SL, Matheson E, Grossmann V, Sinclair P, Bashton M, Schwab C, et al. The role of the RAS pathway in iAMP21-ALL. Leukemia. 2016;30:1824\u201331.","journal-title":"Leukemia."},{"key":"1816_CR19","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nprot.2017.016","volume":"12","author":"J Joung","year":"2017","unstructured":"Joung J, Konermann S, Gootenberg JS, Abudayyeh OO, Platt RJ, Brigham MD, et al. Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening. Nat Protoc. 2017;12:828\u201363.","journal-title":"Nat Protoc"},{"key":"1816_CR20","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nmeth.3047","volume":"11","author":"NE Sanjana","year":"2014","unstructured":"Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods. 2014;11:783\u20134.","journal-title":"Nat Methods"},{"key":"1816_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0554-4","volume":"15","author":"W Li","year":"2014","unstructured":"Li W, Xu H, Xiao T, Cong L, Love MI, Zhang F, et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens. Genome Biol. 2014;15:554.","journal-title":"Genome Biol"},{"key":"1816_CR22","first-page":"2618","volume":"58","author":"S Takeuchi","year":"1998","unstructured":"Takeuchi S, Koike M, Seriu T, Bartram CR, Schrappe M, Reiter A, et al. Frequent loss of heterozygosity on the long arm of chromosome 6: identification of two distinct regions of deletion in childhood acute lymphoblastic leukemia. Cancer Res. 1998;58:2618\u201323.","journal-title":"Cancer Res"},{"key":"1816_CR23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/(SICI)1098-2264(200001)27:1<52::AID-GCC7>3.0.CO;2-X","volume":"27","author":"Y Zhang","year":"2000","unstructured":"Zhang Y, Matthiesen P, Harder S, Siebert R, Castoldi G, Calasanz MJ, et al. A 3-cM commonly deleted region in 6q21 in leukemias and lymphomas delineated by fluorescence in situ hybridization. Genes Chromosomes Cancer. 2000;27:52\u20138.","journal-title":"Genes Chromosomes Cancer"},{"key":"1816_CR24","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/ng.3230","volume":"47","author":"AK Andersson","year":"2015","unstructured":"Andersson AK, Ma J, Wang J, Chen X, Gedman AL, Dang J, et al. The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat Genet. 2015;47:330\u20137.","journal-title":"Nat Genet"},{"key":"1816_CR25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/sj.leu.2400566","volume":"11","author":"B Gerard","year":"1997","unstructured":"Gerard B, Cave H, Guidal C, Dastugue N, Vilmer E, Grandchamp B. Delineation of a 6 cM commonly deleted region in childhood acute lymphoblastic leukemia on the 6q chromosomal arm. Leukemia. 1997;11:228\u201332.","journal-title":"Leukemia."},{"key":"1816_CR26","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1182\/blood.V93.2.613","volume":"93","author":"Y Hatta","year":"1999","unstructured":"Hatta Y, Yamada Y, Tomonaga M, Miyoshi I, Said JW, Koeffler HP. Detailed deletion mapping of the long arm of chromosome 6 in adult T-cell leukemia. Blood 1999;93:613\u20136.","journal-title":"Blood"},{"key":"1816_CR27","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1023\/A:1018418224660","volume":"5","author":"T Sherratt","year":"1997","unstructured":"Sherratt T, Morelli C, Boyle JM, Harrison CJ. Analysis of chromosome 6 deletions in lymphoid malignancies provides evidence for a region of minimal deletion within a 2-megabase segment of 6q21. Chromosome Res. 1997;5:118\u201324.","journal-title":"Chromosome Res"},{"key":"1816_CR28","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3109\/10428194.2014.953155","volume":"56","author":"M Boi","year":"2015","unstructured":"Boi M, Zucca E, Inghirami G, Bertoni F. PRDM1\/BLIMP1: a tumor suppressor gene in B and T cell lymphomas. Leuk Lymphoma. 2015;56:1223\u20138.","journal-title":"Leuk Lymphoma"},{"key":"1816_CR29","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1182\/blood-2014-07-590570","volume":"124","author":"MJ Vogel","year":"2014","unstructured":"Vogel MJ, Xie L, Guan H, Tooze RM, Maier T, Kostezka U, et al. FOXO1 repression contributes to block of plasma cell differentiation in classical Hodgkin lymphoma. Blood. 2014;124:3118\u201329.","journal-title":"Blood."},{"key":"1816_CR30","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1182\/blood-2017-07-795278","volume":"131","author":"CD Osswald","year":"2018","unstructured":"Osswald CD, Xie L, Guan H, Herrmann F, Pick SM, Vogel MJ, et al. Fine-tuning of FOXO3A in cHL as a survival mechanism and a hallmark of abortive plasma cell differentiation. Blood. 2018;131:1556\u201367.","journal-title":"Blood."},{"key":"1816_CR31","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1038\/s41375-019-0412-1","volume":"33","author":"PB Sinclair","year":"2019","unstructured":"Sinclair PB, Ryan S, Bashton M, Hollern S, Hanna R, Case M, et al. SH2B3 inactivation through CN-LOH 12q is uniquely associated with B-cell precursor ALL with iAMP21 or other chromosome 21 gain. Leukemia. 2019;33:1881\u201394.","journal-title":"Leukemia."},{"key":"1816_CR32","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1093\/hmg\/ddq224","volume":"19","author":"H Lilljebjorn","year":"2010","unstructured":"Lilljebjorn H, Soneson C, Andersson A, Heldrup J, Behrendtz M, Kawamata N, et al. The correlation pattern of acquired copy number changes in 164 ETV6\/RUNX1-positive childhood acute lymphoblastic leukemias. Hum Mol Genet. 2010;19:3150\u20138.","journal-title":"Hum Mol Genet"},{"key":"1816_CR33","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1002\/gcc.20613","volume":"47","author":"H Parker","year":"2008","unstructured":"Parker H, An Q, Barber K, Case M, Davies T, Konn Z, et al. The complex genomic profile of ETV6-RUNX1 positive acute lymphoblastic leukemia highlights a recurrent deletion of TBL1XR1. Genes Chromosomes Cancer. 2008;47:1118\u201325.","journal-title":"Genes Chromosomes Cancer"},{"key":"1816_CR34","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.yexmp.2016.05.010","volume":"101","author":"E Kjeldsen","year":"2016","unstructured":"Kjeldsen E. Oligo-based aCGH analysis reveals cryptic unbalanced der(6)t(X;6) in pediatric t(12;21)-positive acute lymphoblastic leukemia. Exp Mol Pathol. 2016;101:38\u201343.","journal-title":"Exp Mol Pathol"},{"key":"1816_CR35","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1038\/sj.leu.2404879","volume":"21","author":"H Lilljebjorn","year":"2007","unstructured":"Lilljebjorn H, Heidenblad M, Nilsson B, Lassen C, Horvat A, Heldrup J, et al. Combined high-resolution array-based comparative genomic hybridization and expression profiling of ETV6\/RUNX1-positive acute lymphoblastic leukemias reveal a high incidence of cryptic Xq duplications and identify several putative target genes within the commonly gained region. Leukemia. 2007;21:2137\u201344.","journal-title":"Leukemia."},{"key":"1816_CR36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.leukres.2007.03.010","volume":"32","author":"DR Betts","year":"2008","unstructured":"Betts DR, Stanchescu R, Niggli FK, Cohen N, Rechavi G, Amariglio N, et al. SKY reveals a high frequency of unbalanced translocations involving chromosome 6 in t(12;21)-positive acute lymphoblastic leukemia. Leuk Res. 2008;32:39\u201343.","journal-title":"Leuk Res"},{"key":"1816_CR37","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1038\/ni.1667","volume":"9","author":"HS Dengler","year":"2008","unstructured":"Dengler HS, Baracho GV, Omori SA, Bruckner S, Arden KC, Castrillon DH, et al. Distinct functions for the transcription factor Foxo1 at various stages of B cell differentiation. Nat Immunol. 2008;9:1388\u201398.","journal-title":"Nat Immunol"},{"key":"1816_CR38","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1182\/bloodadvances.2018029546","volume":"3","author":"P Zhou","year":"2019","unstructured":"Zhou P, Blain AE, Newman AM, Zaka M, Chagaluka G, Adlar FR, et al. Sporadic and endemic Burkitt lymphoma have frequent FOXO1 mutations but distinct hotspots in the AKT recognition motif. Blood Adv. 2019;3:2118\u201327.","journal-title":"Blood Adv"},{"key":"1816_CR39","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1182\/blood-2011-09-381905","volume":"119","author":"L Xie","year":"2012","unstructured":"Xie L, Ushmorov A, Leithauser F, Guan H, Steidl C, Farbinger J, et al. FOXO1 is a tumor suppressor in classical Hodgkin lymphoma. Blood. 2012;119:3503\u201311.","journal-title":"Blood."},{"key":"1816_CR40","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/leu.2012.220","volume":"27","author":"DA Casolari","year":"2013","unstructured":"Casolari DA, Makri M, Yoshida C, Muto A, Igarashi K, Melo JV. Transcriptional suppression of BACH2 by the Bcr-Abl oncoprotein is mediated by PAX5. Leukemia. 2013;27:409\u201315.","journal-title":"Leukemia."},{"key":"1816_CR41","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1038\/s41590-019-0468-0","volume":"20","author":"M Mandal","year":"2019","unstructured":"Mandal M, Okoreeh MK, Kennedy DE, Maienschein-Cline M, Ai J, McLean KC, et al. CXCR4 signaling directs Igk recombination and the molecular mechanisms of late B lymphopoiesis. Nat Immunol. 2019;20:1393\u2013403.","journal-title":"Nat Immunol"},{"key":"1816_CR42","doi-asserted-by":"crossref","unstructured":"Bhansali RS, Rammohan M, Lee P, Laurent AP, Wen Q, Suraneni P, et al. DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3. J Clin Invest. 2021;131:e135937.","DOI":"10.1172\/JCI135937"},{"key":"1816_CR43","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1182\/blood-2017-10-813576","volume":"131","author":"F Wang","year":"2018","unstructured":"Wang F, Demir S, Gehringer F, Osswald CD, Seyfried F, Enzenmuller S, et al. Tight regulation of FOXO1 is essential for maintenance of B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131:2929\u201342.","journal-title":"Blood."},{"key":"1816_CR44","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/gcc.22765","volume":"58","author":"AJ de Smith","year":"2019","unstructured":"de Smith AJ, Lavoie G, Walsh KM, Aujla S, Evans E, Hansen HM, et al. Predisposing germline mutations in high hyperdiploid acute lymphoblastic leukemia in children. Genes Chromosomes Cancer. 2019;58:723\u201330.","journal-title":"Genes Chromosomes Cancer"},{"key":"1816_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7604","volume":"6","author":"X Ma","year":"2015","unstructured":"Ma X, Edmonson M, Yergeau D, Muzny DM, Hampton OA, Rusch M, et al. Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. Nat Commun. 2015;6:6604.","journal-title":"Nat Commun"},{"key":"1816_CR46","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nature09727","volume":"471","author":"CG Mullighan","year":"2011","unstructured":"Mullighan CG, Zhang J, Kasper LH, Lerach S, Payne-Turner D, Phillips LA, et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature. 2011;471:235\u20139.","journal-title":"Nature."},{"key":"1816_CR47","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nature21076","volume":"542","author":"LN Chan","year":"2017","unstructured":"Chan LN, Chen Z, Braas D, Lee JW, Xiao G, Geng H, et al. Metabolic gatekeeper function of B-lymphoid transcription factors. Nature. 2017;542:479\u201383.","journal-title":"Nature."},{"key":"1816_CR48","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.15252\/embj.201796700","volume":"36","author":"MR Woodford","year":"2017","unstructured":"Woodford MR, Sager RA, Marris E, Dunn DM, Blanden AR, Murphy RL, et al. Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding of kinase and non-kinase clients. EMBO J. 2017;36:3650\u201365.","journal-title":"EMBO J"},{"key":"1816_CR49","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"A Chari","year":"2019","unstructured":"Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, et al. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. N Engl J Med. 2019;381:727\u201338.","journal-title":"N Engl J Med"},{"key":"1816_CR50","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/leu.2013.115","volume":"28","author":"YT Tai","year":"2014","unstructured":"Tai YT, Landesman Y, Acharya C, Calle Y, Zhong MY, Cea M, et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 2014;28:155\u201365.","journal-title":"Leukemia."},{"key":"1816_CR51","doi-asserted-by":"publisher","first-page":"805260","DOI":"10.3389\/fimmu.2021.805260","volume":"12","author":"S Nadeau","year":"2021","unstructured":"Nadeau S, Martins GA. Conserved and Unique Functions of Blimp1 in Immune Cells. Front Immunol. 2021;12:805260.","journal-title":"Front Immunol"},{"key":"1816_CR52","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.semcancer.2017.07.008","volume":"50","author":"A Ushmorov","year":"2018","unstructured":"Ushmorov A, Wirth T. FOXO in B-cell lymphopoiesis and B cell neoplasia. Semin Cancer Biol. 2018;50:132\u201341.","journal-title":"Semin Cancer Biol"},{"key":"1816_CR53","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41573-020-0088-2","volume":"20","author":"G Calissi","year":"2021","unstructured":"Calissi G, Lam EW, Link W. Therapeutic strategies targeting FOXO transcription factors. Nat Rev Drug Disco. 2021;20:21\u201338.","journal-title":"Nat Rev Drug Disco"},{"key":"1816_CR54","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1038\/onc.2008.21","volume":"27","author":"DR Calnan","year":"2008","unstructured":"Calnan DR, Brunet A. The FoxO code. Oncogene. 2008;27:2276\u201388.","journal-title":"Oncogene."},{"key":"1816_CR55","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.bcp.2017.11.009","volume":"147","author":"C Corno","year":"2018","unstructured":"Corno C, Stucchi S, De Cesare M, Carenini N, Stamatakos S, Ciusani E, et al. FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models. Biochem Pharm. 2018;147:93\u2013103.","journal-title":"Biochem Pharm"},{"key":"1816_CR56","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/bjh.12231","volume":"161","author":"J Etchin","year":"2013","unstructured":"Etchin J, Sanda T, Mansour MR, Kentsis A, Montero J, Le BT, et al. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol. 2013;161:117\u201327.","journal-title":"Br J Haematol"},{"key":"1816_CR57","doi-asserted-by":"publisher","first-page":"38027","DOI":"10.1074\/jbc.M111.275503","volume":"286","author":"CA Stoltzman","year":"2011","unstructured":"Stoltzman CA, Kaadige MR, Peterson CW, Ayer DE. MondoA senses non-glucose sugars: regulation of thioredoxin-interacting protein (TXNIP) and the hexose transport curb. J Biol Chem. 2011;286:38027\u201334.","journal-title":"J Biol Chem"},{"key":"1816_CR58","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nm.4252","volume":"23","author":"Z Lu","year":"2017","unstructured":"Lu Z, Xie J, Wu G, Shen J, Collins R, Chen W, et al. Fasting selectively blocks development of acute lymphoblastic leukemia via leptin-receptor upregulation. Nat Med. 2017;23:79\u201390.","journal-title":"Nat Med"},{"key":"1816_CR59","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jsbmb.2012.09.011","volume":"136","author":"G Eelen","year":"2013","unstructured":"Eelen G, Verlinden L, Meyer MB, Gijsbers R, Pike JW, Bouillon R, et al. 1,25-Dihydroxyvitamin D3 and the aging-related forkhead box O and sestrin proteins in osteoblasts. J Steroid Biochem Mol Biol. 2013;136:112\u20139.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"1816_CR60","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1126\/scitranslmed.aak9969","volume":"9","author":"E Oricchio","year":"2017","unstructured":"Oricchio E, Katanayeva N, Donaldson MC, Sungalee S, Pasion JP, Beguelin W, et al. Genetic and epigenetic inactivation of SESTRIN1 controls mTORC1 and response to EZH2 inhibition in follicular lymphoma. Sci Transl Med. 2017;9:396.","journal-title":"Sci Transl Med"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01816-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01816-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01816-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T08:29:32Z","timestamp":1710923372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01816-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,20]]},"references-count":60,"alternative-id":["1816"],"URL":"https:\/\/doi.org\/10.1038\/s41375-023-01816-0","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"type":"print","value":"0887-6924"},{"type":"electronic","value":"1476-5551"}],"subject":[],"published":{"date-parts":[[2023,1,20]]},"assertion":[{"value":"23 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}